The primary focus of smoking cessation research has been adults in the past, but a new study zeroed in on adolescents. This study found that while there was no significant difference between the varenicline group and the placebo group at end of treatment, those in the varenicline group quit earlier in the trial and were less likely to relapse after the trial was over. And it encourages new treatments designs for adolescents.